Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMCC NASDAQ:LSB NASDAQ:PHXM NASDAQ:SRNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMCCIM Cannabis$1.93-2.0%$2.14$1.29▼$7.12$10.13M2.13108,439 shs91,461 shsLSBLakeShore Biopharma$0.53-33.0%$0.71$0.57▼$8.60$11.01M0.5683,626 shs819,833 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/ASRNESorrento Therapeutics$0.01+40.0%$0.00$0.00▼$0.10$3.86M1.19138,199 shs104,624 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMCCIM Cannabis+1.03%-1.50%+2.07%-41.02%-8.04%LSBLakeShore Biopharma0.00%0.00%-34.16%-52.25%-85.98%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%SRNESorrento Therapeutics+40.00%+55.56%+100.00%+337.50%+118.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMCCIM Cannabis$1.93-2.0%$2.14$1.29▼$7.12$10.13M2.13108,439 shs91,461 shsLSBLakeShore Biopharma$0.53-33.0%$0.71$0.57▼$8.60$11.01M0.5683,626 shs819,833 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/ASRNESorrento Therapeutics$0.01+40.0%$0.00$0.00▼$0.10$3.86M1.19138,199 shs104,624 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMCCIM Cannabis+1.03%-1.50%+2.07%-41.02%-8.04%LSBLakeShore Biopharma0.00%0.00%-34.16%-52.25%-85.98%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%SRNESorrento Therapeutics+40.00%+55.56%+100.00%+337.50%+118.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMCCIM Cannabis 1.00SellN/AN/ALSBLakeShore Biopharma 0.00N/AN/AN/APHXMPHAXIAM Therapeutics 0.00N/AN/AN/ASRNESorrento Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SRNE, LSB, PHXM, and IMCC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025IMCCIM CannabisWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025IMCCIM CannabisWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMCCIM Cannabis$39.44M0.27N/AN/A$1.03 per share1.94LSBLakeShore Biopharma$85.67M0.13N/AN/A$3.35 per share0.16PHXMPHAXIAM TherapeuticsN/AN/AN/AN/A$7.98 per shareN/ASRNESorrento Therapeutics$60.32M0.06N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMCCIM Cannabis-$7.72M-$0.54N/AN/AN/A-4.19%-59.80%-5.15%11/13/2025 (Estimated)LSBLakeShore Biopharma-$13.93MN/A0.00∞N/AN/AN/AN/A10/30/2025 (Estimated)PHXMPHAXIAM Therapeutics-$240KN/A0.00∞N/AN/AN/AN/AN/ASRNESorrento Therapeutics-$572.84MN/A0.00∞N/AN/AN/AN/AN/ALatest SRNE, LSB, PHXM, and IMCC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025IMCCIM Cannabis-$0.1367-$0.0653+$0.0714-$0.07$12.88 million$9.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMCCIM CannabisN/AN/AN/AN/AN/ALSBLakeShore BiopharmaN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/ASRNESorrento TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMCCIM Cannabis0.320.720.62LSBLakeShore Biopharma0.051.020.75PHXMPHAXIAM Therapeutics0.231.78N/ASRNESorrento TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMCCIM Cannabis7.68%LSBLakeShore Biopharma52.64%PHXMPHAXIAM Therapeutics0.40%SRNESorrento Therapeutics0.02%Insider OwnershipCompanyInsider OwnershipIMCCIM Cannabis5.91%LSBLakeShore BiopharmaN/APHXMPHAXIAM Therapeutics1.94%SRNESorrento Therapeutics2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMCCIM Cannabis3405.25 million4.94 millionNot OptionableLSBLakeShore Biopharma77320.77 millionN/AN/APHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataSRNESorrento Therapeutics800551.28 million536.95 millionNo DataSRNE, LSB, PHXM, and IMCC HeadlinesRecent News About These CompaniesSorrento Therapeutics Inc (SRNE) - Investing.comJuly 3, 2025 | investing.comSRNE Sorrento Therapeutics, Inc. - Seeking AlphaJune 29, 2025 | seekingalpha.comSorrento Therapeutics Stock Price, Quotes and Forecasts | OTC:SRNE | BenzingaApril 19, 2025 | benzinga.comSorrento Shareholders Lose Discovery Bid Over Judge RelationshipMarch 28, 2025 | news.bloomberglaw.comNScilex says bankruptcy court extends lockup period on shares of Scilex dividendJanuary 31, 2025 | markets.businessinsider.comDSI Introduces Westbury Sorrento Aluminum Railing with Bold Distinctive Mesh Stainless Steel InfillsOctober 24, 2024 | newsfilecorp.comNSorrento enrols 60 of 80-patient Phase II target for abivertinib in Covid-19; futility analysis potentially in a month, CEO saysAugust 20, 2024 | msn.comSorrento Resources to Sell Three Newfoundland Properties to Gold HunterMay 29, 2024 | newsfilecorp.comNSorrento Therapeutics Inc (SRNE)May 25, 2024 | investing.comSorrento Resources Announces Appointment of Alex Bugden as a Director and Qualified PersonMay 8, 2024 | newsfilecorp.comNDSI Introduces Westbury(R) Sorrento Aluminum and Stainless Steel Mesh RailingMay 1, 2024 | newsfilecorp.comNSorrento Therapeutics Inc SRNEApril 26, 2024 | morningstar.comMSorrento Therapeutics Wins Appeal Over Covid Treatment RemarksMarch 27, 2024 | news.bloomberglaw.comNSorrento Therapeutics Wins Appeal Over Covid Treatment RemarksMarch 27, 2024 | news.bloomberglaw.comNSorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1)March 12, 2024 | news.bloomberglaw.comNJudge Declines to Dismiss Sorrento Therapeutics Bankruptcy CaseMarch 12, 2024 | wsj.comVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.February 27, 2024 | tmcnet.comVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.February 27, 2024 | businesswire.comSorrento TherapeuticsFebruary 7, 2024 | pharmaphorum.comP5 Sanders Cove, Sorrento WA 6020January 18, 2024 | domain.com.auDNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSRNE, LSB, PHXM, and IMCC Company DescriptionsIM Cannabis NASDAQ:IMCC$1.93 -0.04 (-2.03%) As of 03:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.LakeShore Biopharma NASDAQ:LSB$0.53 -0.26 (-32.95%) Closing price 09/19/2025Extended Trading$0.53 0.00 (0.00%) As of 09/19/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.PHAXIAM Therapeutics NASDAQ:PHXM$3.10 0.00 (0.00%) As of 10/10/2025PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.Sorrento Therapeutics NASDAQ:SRNE$0.0070 +0.00 (+40.00%) As of 02:26 PM EasternSorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
